COVID-19: Novartis to begin HCQ trials

Even as there is still question hanging over the efficacy of hydroxychloroquine (HCQ) as medication for Covid-19, Swiss drug maker Novartis announced trials to evaluate use of HCQ for the treatment of hospitalised patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3czwFWX
via IFTTT